On May 15, 2025, analyst Ross Osborn from Cantor Fitzgerald released an updated stock analysis on Exagen (XGN, Financial). The latest report maintains the company's current rating at "Overweight," unchanged from its prior assessment.
However, there has been a shift in the price target for Exagen (XGN, Financial). The price target has been lowered from a previous valuation of $8.00 USD to $7.00 USD. This adjustment reflects a 12.50% decrease.
Exagen (XGN, Financial) continues to be closely monitored by investors and analysts following this update. The company's performance and market position remain central to forthcoming evaluations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Exagen Inc (XGN, Financial) is $7.75 with a high estimate of $9.00 and a low estimate of $7.00. The average target implies an upside of 31.24% from the current price of $5.91. More detailed estimate data can be found on the Exagen Inc (XGN) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Exagen Inc's (XGN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Exagen Inc (XGN, Financial) in one year is $3.55, suggesting a downside of 39.88% from the current price of $5.905. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Exagen Inc (XGN) Summary page.
